{"id":"NCT04490018","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents","officialTitle":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix®, and When Administered Alone or Concomitantly With 9vHPV and Tdap-IPV Vaccines in Healthy Adolescents","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-03-16","primaryCompletion":"2022-05-11","completion":"2022-05-11","firstPosted":"2020-07-28","resultsPosted":"2023-06-06","lastUpdate":"2023-10-03"},"enrollment":463,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Meningococcal Immunisation","Healthy Volunteers"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate vaccine)","otherNames":["MenQuadfi®"]},{"type":"BIOLOGICAL","name":"Meningococcal group A, C, W-135, and Y conjugate vaccine","otherNames":["Nimenrix®"]},{"type":"BIOLOGICAL","name":"Human Papillomavirus 9-valent Vaccine (9vHPV)","otherNames":["Gardasil® 9"]},{"type":"BIOLOGICAL","name":"Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine (Tdap-IPV)","otherNames":["Repevax®/Triaxis®/Adacel®Polio"]}],"arms":[{"label":"Group 1: MenACYW Conjugate Vaccine + 9vHPV + Tdap-IPV Vaccines (Sequential Administration)","type":"EXPERIMENTAL"},{"label":"Group 2: Nimenrix® + 9vHPV + Tdap-IPV Vaccines (Sequential Administration)","type":"ACTIVE_COMPARATOR"},{"label":"Group 3: MenACYW Conjugate Vaccine + 9vHPV + Tdap-IPV Vaccines (Concomitant Administration)","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\nTo demonstrate the non-inferiority of the seroprotection rate (serum bactericidal assay using human complement \\[hSBA\\] titer greater than or equal to \\[\\>=\\] 1:8) to meningococcal serogroups A, C, W, and Y following the administration of a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate vaccine (MenACYW Conjugate vaccine) (Group 1) compared to a single dose of Nimenrix® (Group 2).\n\nSecondary Objective:\n\nTo describe:\n\n* the antibody response of meningococcal serogroups A, C, W, and Y measured by hSBA, before and 1 month following meningococcal vaccination administered alone (Groups 1 and 2) or concomitantly with 9-valent human papilloma virus (9vHPV) and tetanus, diphtheria, and acellular pertussis - inactivated polio vaccine \\[adsorbed, reduced antigen(s) content\\] (Tdap-IPV) vaccines (Group 3).\n* the antibody response of meningococcal serogroup C measured by hSBA and serum bactericidal assay using baby rabbit complement (rSBA), before vaccination and at Day 31 after vaccination with MenACYW Conjugate vaccine or Nimenrix® (Groups 1 and 2) according to MenC primed status.\n* the antibody response against antigens of 9vHPV and Tdap-IPV vaccines, before and 1 month following vaccination.\n* the safety profile in each group after each and any vaccination.","primaryOutcome":{"measure":"Percentage of Participants With Antibody Titers >=1:8 Against Meningococcal Serogroups A, C, W, and Y Measured by hSBA Following Vaccination With MenACYW Conjugate Vaccine or Nimenrix® Vaccine (Non-inferiority Analysis): Groups 1 and 2","timeFrame":"Day 31 (post-vaccination)","effectByArm":[{"arm":"Group 1: MenACYW Conjugate Vaccine + 9vHPV + Tdap-IPV Vaccines (Sequential Administration)","deltaMin":97.5,"sd":null},{"arm":"Group 2: Nimenrix® + 9vHPV + Tdap-IPV Vaccines (Sequential Administration)","deltaMin":92.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":23},"locations":{"siteCount":23,"countries":["Hungary","Italy","Singapore","Spain"]},"refs":{"pmids":["38955966"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":171},"commonTop":["Injection Site Pain","Myalgia","Headache","Malaise","Injection Site Erythema"]}}